ELI LILLY & Co is 27.8x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $38.52 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALNY | LLY |
|---|---|---|
| Market cap | $38.52 B | $1.070 T |
| US-listed rank | #396 | #10 |
| Revenue (latest FY) | $3.71B | $65.18B |
| Net income (latest FY) | $313.75M | $20.64B |
| Net margin | 8.4% | 31.7% |
| P/E (trailing FY) | 122.8 | 51.8 |
| SEC filings | 1,651 | 989 |
ELI LILLY & Co is 27.8x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $38.52 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.